- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03794232
Effect of Inulin-type Fructose Extracted From Jerusalem Artichoke on Improving Prediabetic State of Type 2 Diabetes
Study on the Mechanisms of Soluble Dietary Fiber Extracted From Jerusalem Artichoke in the Treatment of Pre-type 2 Diabetes
The trial was a multicenter, randomized, double-blind, placebo-controlled, parallel-controlled, exploratory clinical study.Through the intervention of soluble dietary fiber in the pre-type 2 diabetic population, the change of blood glucose spectrum before and after intervention can show the effect of this intervention on the outcome, and further elucidate the effect of soluble dietary fiber intervention on the level of insulin resistance and its effect on outcome. Helps to prevent the more scientific and effective prevention of type 2 diabetes from pre-diabetes.
Subjects who met the criteria were randomly divided into the experimental group and the control group, after 24 weeks of intervention, the incidence of blood sugar reversion to normal was main observed.The main purpose of this study was to investigate the effect of soluble dietary fiber treatment regimens on the conversion rate of pre-type 2 diabetes (converted to normal blood glucose, type 2 diabetes, or stable in the stage of impaired glucose tolerance). The secondary objective was to study the improvement of insulin resistance and changes in intestinal flora after intervention.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The soluble dietary fiber (NIUCHANG®) and placebo used in the trial were exclusively produced by Inuling (Beijing) Technology Co., Ltd. and provided free of charge. During the treatment period, the treatment group was given oral "NIUCHANG®" (once 15g,once a day)and the control group was given oral placebo (once15 g, once a day) for 24 weeks.
The test was performed for 12 weeks as a course of treatment。At the end of one course of treatment, if the glucose tolerance was changed to normal or the blood glucose was stable in the pre-diabetes phase, the original dose was maintained and continued for 12 weeks. At 24 weeks, patients with normal blood glucose and glucose tolerance tests were followed up for 48 weeks. At the end of one course of treatment, if the blood glucose progresses to the stage of diabetes, the test is withdrawn and treated according to clinical routine.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
The following various situations need to be met at the same time in order to be selected:
- According to the diagnostic criteria for impaired glucose tolerance in the WHO Diabetes Diagnosis and Classification Standard in 1999: fasting blood glucose ≥6.1mmol/L and <7.0mmol/L, blood glucose 2 hours after oral administration of 75g glucose ≥7.8mmol/L and < 11.1mmol/L;
- BMI:20kg/㎡ ≤ BMI ≤ 35kg/㎡;
- Age ≥ 18 and ≤ 70 years old, gender is not limited;
- Voluntarily participate in the trial and sign the informed consent form.
Exclusion Criteria:
Any of the following circumstances should be excluded and cannot be selected:
- Acute cardiovascular and cerebrovascular events or myocardial infarction within 6 months;
- Laboratory examination: liver function AST or ALT ≥ 2.5 × ULN; renal function Cr > 1.2 × ULN;
- Those with severe gastrointestinal diseases, such as active peptic ulcer, intestinal obstruction, etc.; those who have changed the history of normal structure of the gastrointestinal tract;
- Hypertensive patients with poor blood pressure control (blood pressure SBP ≥ 160 mmHg and / or DBP ≥ 100 mmHg);
- Those with severe blood system diseases;
- Those with other endocrine system diseases, such as hyperthyroidism or hypercortisolism;
- Those who have a stress state or have secondary blood glucose elevation factors (such as those who take glucocorticoids);
- Women who are pregnant or breast-feeding, who are planning to be pregnant or who are not willing to contraception during the study;
- Drug or other drug abusers;
- Those who may be allergic to the test drug;
- Those who have participated in other drug trials within 3 months;
- Those who are unable to cooperate with mental illness;
- Other circumstances The investigator believes that it is not suitable for the group.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Test group
NIUCHANG(Soluble dietary fiber + prebiotics):Oral, 1 bag (15g) once a day, taking 24 weeks
|
|
Placebo Comparator: Control group
Placebo(inactive drug ingredient):Oral, 1 bag (15g) once a day, taking 24 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of blood sugar reversal to normal after intervention
Time Frame: Day 0, Week 24
|
Through the intervention of soluble dietary fiber in the pre-diabetic population, the change of blood glucose spectrum before and after intervention can show the effect of this intervention on the outcome, and further elucidate the effect of soluble dietary fiber intervention on the level of insulin resistance and its effect on outcome.
|
Day 0, Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in insulin resistance index
Time Frame: Day 0, Week 24
|
the incidence of blood sugar reversion to normal was main observed
|
Day 0, Week 24
|
Changes in intestinal flora
Time Frame: Day 0, Week1,Week4,Week12,Week 24
|
If the subject has had diarrhea or taking antibiotics 2 days before and after the fecal specimen should be taken, wait for the stagnation for 1 week before taking the stool specimen to reduce the interference of external factors.
|
Day 0, Week1,Week4,Week12,Week 24
|
Incidence of blood glucose stabilization in pre-diabetes after intervention
Time Frame: Day 0, Week12,Week 24
|
blood glucose becomes stable
|
Day 0, Week12,Week 24
|
Incidence of blood glucose progression to diabetes after intervention
Time Frame: Day 0, Week12,Week 24
|
reduce incidence of blood glucose progression
|
Day 0, Week12,Week 24
|
Hemoglobin A1C、Glycated Albumin
Time Frame: Day 0, Week 24
|
Changes of Hemoglobin A1C and Glycated Albumin.
|
Day 0, Week 24
|
The levels of serum insulin
Time Frame: Day 0, Week 24
|
Insulin levels were measured on an empty stomach, 30 minutes, 60 minutes and 120 minutes after oral administration of 75 g of glucose.
|
Day 0, Week 24
|
The levels of serum C-peptid
Time Frame: Day 0, Week 24
|
C-peptide levels were measured on an empty stomach, 30 minutes, 60 minutes and 120 minutes after oral administration of 75 g of glucose.
|
Day 0, Week 24
|
Body weight
Time Frame: Day 0, Week12,Week 24
|
Changes of body weight.
|
Day 0, Week12,Week 24
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- S-749
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prediabetes
-
Aga Khan UniversityLinnaeus University; Kenyatta UniversityRecruiting
-
Philip KernNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
Chonbuk National University HospitalCompletedPreDiabetes
-
TNOWageningen University and Research; Google LLC.; Jumbo Supermarkten Bv.; Noldus...Completed
-
University of TorontoInternational Nut and Dried Fruit Council (INC); The National Dried Fruit Trade... and other collaboratorsUnknown
-
Albert Einstein College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Clinical Nutrition Research Centre, SingaporeSingapore Institute for Clinical SciencesCompleted
-
Northwestern UniversityAllianceChicago; Erie Family Health CentersCompleted
-
Ohio UniversityTouro University, CaliforniaCompletedPreDiabetes
-
Chinese Association of Geriatric ResearchCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States